Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan.
Helicobacter. 2012 Dec;17(6):466-77. doi: 10.1111/j.1523-5378.2012.00992.x. Epub 2012 Aug 28.
The current therapy for Helicobacter pylori infection includes antimicrobial agents and proton pump inhibitors. We have examined the ability of Lactobacillus spp. to inhibit H. pylori infection.
Probiotic strains isolated from samples of adult feces, infant feces, breast milk, and vaginal swab collected from healthy volunteers in Taiwan and commercially available strains were screened for antagonism toward H. pylori. Inhibition liquid culture assay was used to screen potential anti-H. pylori activity. Then, we performed agar plate inhibition assay, and assays to determine the capacity of probiotics for adhesion, and inhibition and killing of H. pylori, and measured the levels of IL-8 and IL-10. Using animal models, we studied regulation of gastric acid and histopathological changes accompanying anti-H. pylori activity.
We found that six of the tested strains suppressed urease activity of H. pylori: Lactobacillus acidophilus TYCA08, L. acidophilus TYCA15, L. johnsonii MH-68, and L. salivarius subsp. salicinius AP-32 were more effective than the others. In vivo, L. johnsonii MH-68 and L. salivarius subsp. salicinius AP-32 alone or in combination, reduced the H. pylori load in the gastric mucosa, and also reduced inflammatory chemokine expression and lymphocyte infiltration.
Lactobacillus johnsonii MH-68 and L. salivarius subsp. salicinius AP-32 effectively suppress H. pylori viability, and when used as probiotics, they may help decrease the occurrence of gastritis, and even reduce the risk of H. pylori infection.
目前治疗幽门螺杆菌感染的方法包括使用抗生素和质子泵抑制剂。我们研究了乳酸杆菌属抑制幽门螺杆菌感染的能力。
从台湾健康志愿者的粪便、母乳、阴道拭子样本中分离出益生菌株，并筛选对幽门螺杆菌具有拮抗作用的商业菌株。采用抑制液体培养试验筛选潜在的抗幽门螺杆菌活性。然后，我们进行琼脂板抑制试验、益生菌黏附、抑制和杀灭幽门螺杆菌的能力以及白细胞介素-8（IL-8）和白细胞介素-10（IL-10）水平的检测。利用动物模型，研究了伴随抗幽门螺杆菌活性的胃酸调节和组织病理学变化。
我们发现 6 株受试菌株能抑制幽门螺杆菌的脲酶活性：嗜酸乳杆菌 TYCA08、TYCA15、约氏乳杆菌 MH-68 和唾液乳杆菌亚种 salicinius AP-32 的抑制效果优于其他菌株。体内实验表明，约氏乳杆菌 MH-68 和唾液乳杆菌亚种 salicinius AP-32 单独或联合使用可降低胃黏膜中的幽门螺杆菌负荷，还可降低炎症趋化因子的表达和淋巴细胞浸润。
约氏乳杆菌 MH-68 和唾液乳杆菌亚种 salicinius AP-32 可有效抑制幽门螺杆菌的活力，作为益生菌使用时，可能有助于减少胃炎的发生，甚至降低幽门螺杆菌感染的风险。
